This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Acute myelogenous leukemia (AML)

Integrin b3 (GPIIIa; CD61)

Studies in mice suggest antagonizing CD61 could help treat AML. In a mouse xenograft model for AML, knockdown or deletion of Cd61 slowed leukemia progression and increased survival compared with wild-type Cd61 expression without affecting hematopoiesis. Next steps could include testing anti-CD61 mAbs in mouse models for AML.

SciBX 6(29); doi:10.1038/scibx.2013.747
Published online Aug. 1, 2013

Patent and licensing status undisclosed

Miller, P.G. et al. Cancer Cell; published online June 13, 2013;
doi:10.1016/j.ccr.2013.05.004
Contact: Benjamin L. Ebert, Harvard Medical School, Boston, Mass.
e-mail:
bebert@partners.org